Executive Summary
Azoth Analytics has released a research report titled "United States Endometriosis and Uterine Fibroids Market (2024 Edition)" which provides a complete analysis of the United States Endometriosis and Uterine Fibroids industry in terms of market segmentation By Drug Type (GnRH Antagonists, Progesterone, GnRh Agonist and Others), By Route of Administration (Oral, and Parenteral), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030.
The United States Endometriosis and Uterine Fibroids Market showcased growth at a CAGR of 4.09 % during 2020-2023. The market was valued at USD 415.70 Million in 2023 which is expected to reach USD 568.07 Million in 2030. The United States has been experiencing a significant boom in recent years, driven by growing prevalence of the disease due to technological advancements in the diagnostics techniques in the United States, increased awareness towards reproductive disorders, and increased expenditure of capital in the Research and Development organizations in the United States.
Due to the limited number of drugs available for the treatment of Endometriosis and Uterine Fibroids, it becomes imperative to find novel treatment outcomes for enhancing the quality of life of the patients. Surgical removal of the fibroids is the only effective treatment option available for treating the disease. However, many females prefer drug therapies over surgical procedures as they are non-invasive. Endometriosis, on the other hand not only affects the uterus but, it also spreads to other reproductive organs, if not treated properly.
Increased investments by pharmaceutical companies on exploring the efficacy of different classes of hormonal drugs can pave way for a new drug in the market through different routes of administration such as oral, and parenteral. The emergence of newer technologies such as nanocarrier delivery of drugs, skin patches for epidermal drug delivery have increased the preference for drug therapies in the United States.
The landscape of drug development in United States has changed dramatically. Precision medicine has emerged as a result of the elimination of conventional treatment options available for endometriosis and uterine fibroids. Clinicians can prescribe medications based on the clinical presentation, genetic profile, and the severity or stage of endometriosis. Scientists have focused their research on developing tailored medicines for the treatment of endometriosis and uterine fibroids by utilising high resolution omics data and meta-analysis of disease profile.
New avenues in the research and development for endometriosis and uterine fibroids treatment have been made possible by incorporating artificial intelligence and machine learning in drug manufacturing processes. Various distribution channels such as Hospital pharmacies, retail pharmacies or online pharmacies offers widespread delivery of medicine to the consumers especially for those living in remote areas or facing time constraints. In the coming years, the online channels have the potential to elevate the market sales of drugs.
Furthermore, the use of biodegradable implants for delivering hormonal drugs such as progesterone, Gonadotrophin releasing hormone agonists, and Gonadotrophin releasing agonists is one of the trends in the United States endometriosis and uterine fibroid market. These biodegradable implants are biocompatible and non-invasive in nature. In addition to these benefits, drug implants consume less time and can be implemented in the case of controlling the symptoms associated with the diseases.
Scope of the Report:
•The report analyses the Global, Americas and United States Endometriosis and Uterine Fibroids Market by Value (USD Million).
•The report includes a detailed assessment of United States Endometriosis and Uterine Fibroids Market by Value (USD Million).
•The report analyses the United States Endometriosis and Uterine Fibroids Market by Epidemiology.
•The report analyses the United States Endometriosis and Uterine Fibroids Market by Pipeline Scenario.
•The report presents the analysis of United States Endometriosis and Uterine Fibroids Market for the historical period of 2020-2023, the estimated year 2024, and the forecast period of 2025-2030.
•The report analyses the United States Endometriosis and Uterine Fibroids Market, By Drug Type (GnRH Antagonists, Progesterone, GnRh Agonist and Others).
•The report analyses the United States Endometriosis and Uterine Fibroids Market By Route of Administration (Oral and Parenteral).
•The report analyses the United States Endometriosis and Uterine Fibroids Market By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies).
•The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented By Drug Type, by Route of Administration & by Distribution Channel.
•Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
•The report tracks competitive developments, strategies, mergers and acquisitions and new Drug development. The companies analysed in the report include AbbVie Inc., Pfizer Inc., AstraZeneca plc., Tolmar Inc., Glenmark Pharmaceuticals Pvt. Ltd., Aspen Pharmacare Holdings Ltd., Agile Therapeutics Inc., Medicine 360, Cipla Ltd., Takeda Pharmaceuticals.
Table of Content
1. Market Background
1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology
2. Analyst Recommendations
2.1 Augment the availability of combinational drugs
2.2 Escalate Distribution through Online services
3. Global Endometriosis and Uterine Fibroids Market: Historic and Forecast
3.1 Impact Analysis of Macro Economic Factors on Global Endometriosis and Uterine Fibroids Market
3.2 Global Endometriosis and Uterine Fibroids Market: Dashboard
3.3 Global Endometriosis and Uterine Fibroids Market: Market Value Assessment3.4 Regional Snapshot
4. Americas Endometriosis and Uterine Fibroids Market
4.1 Americas Endometriosis and Uterine Fibroids Market: Market Value Assessment
4.2 Americas Endometriosis and Uterine Fibroids Market: Key Factors
4.3 Americas Endometriosis and Uterine Fibroids Market: Segment Analysis
4.4 Americas Endometriosis and Uterine Fibroids Market: By Country Overview
5. United States Endometriosis and Uterine Fibroids Market
5.1 United States Endometriosis and Uterine Fibroids: Dashboard
5.2 United States Endometriosis and Uterine Fibroids: Market Value Assessment
5.3 United States Endometriosis and Uterine Fibroids: By Drug Type
5.3.1 United States Endometriosis and Uterine Fibroids Market, By Drug Type Overview
5.3.2 United States Endometriosis and Uterine Fibroids Market Size, By GnRH Antagonists, By Value, 2020H-2030F (USD Million & CAGR)
5.3.3 United States Endometriosis and Uterine Fibroids Market Size, By Progesterone, By Value, 2020H-2030F (USD Million & CAGR)
5.3.4 United States Endometriosis and Uterine Fibroids Market Size, By GnRH Agonists, By Value, 2020H-2030F (USD Million & CAGR)
5.3.5 United States Endometriosis and Uterine Fibroids Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
5.4 United States Endometriosis and Uterine Fibroids: By Route of Administration
5.4.1 United States Endometriosis and Uterine Fibroids Market, By Route of Administration Overview
5.4.2 United States Endometriosis and Uterine Fibroids Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
5.4.3 United States Endometriosis and Uterine Fibroids Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
5.3.4 United States Endometriosis and Uterine Fibroids Market Size, By Online Pharmacies, By Value, 2020H-2030F (USD Million & CAGR)
5.4 United States Endometriosis and Uterine Fibroids: By Distribution Channel
5.4.1 United States Endometriosis and Uterine Fibroids Market, By Distribution Channel Overview
5.4.2 United States Endometriosis and Uterine Fibroids Market Size, By Hospital Pharmacies, By Value, 2020H-2030F (USD Million & CAGR)
5.4.3 United States Endometriosis and Uterine Fibroids Market Size, By Retail Pharmacies, By Value, 2020H-2030F (USD Million & CAGR)
5.4.4 United States Endometriosis and Uterine Fibroids Market Size, By Online Pharmacies, By Value, 2020H-2030F (USD Million & CAGR)
6. United States Endometriosis and Uterine Fibroids Epidemiology and Pipeline Analysis
6.1 Epidemiology: United States Endometriosis and Uterine Fibroids Prevalence
6.2 Epidemiology: United States Endometriosis and Uterine Fibroids Incidence
6.3 Pipeline Scenario
7. Market Dynamics
7.1 Impact Assessment of Market Dynamics on United States Endometriosis and Uterine Fibroids
7.2 Market Dynamics of United States Endometriosis and Uterine Fibroids: Drivers
7.3 Market Dynamics of United States Endometriosis and Uterine Fibroids: Restraints
7.4 Market Dynamics of United States Endometriosis and Uterine Fibroids: Trends
8. Industry Ecosystem Analysis
8.1 Porter Analysis of United States Endometriosis and Uterine Fibroids Market
9. Competitive Positioning
9.1 Companies Product Positioning
9.2 Market Position Matrix
9.3 Market Share Analysis of United States Endometriosis and Uterine Fibroids Market
9.4 Company Profiles
9.4.1 AbbVie Inc.
9.4.2 Pfizer Inc.
9.4.3 AstraZeneca plc.
9.4.4 Tolmar Inc.
9.4.5 Glenmark Pharmaceuticals Ltd.
9.4.6 Aspen Pharmacare Holdings Ltd.
9.4.7 Agile Therapeutics Inc
9.4.8 Medicines 360
9.4.9 Cipla Ltd
9.4.10 Takeda Pharmaceuticals
10. About us & Disclaimer
Across personal accessories in the UK, product innovation and messaging in 2024 are largely focused around providing experiences and value to consumers. As discretionary spending on non-essential categories continues to suffer, retail volume growth remains low as consumers further adapt to their cur...
Jewellery in the UK is experiencing a weak performance in 2024, with limited retail value sales growth and a marginal decline in volume sales. This is largely being driven by declining consumer spending on discretionary categories such as jewellery in a turbulent economic landscape. While in previou...
Within traditional and connected watches in the UK, the pursuit of value remains a key driver of consumer purchasing behaviour in 2024. Retail volume sales of traditional watches continue to decline, largely due to shifts in consumption in the face of declining discretionary spending, while value gr...
In 2024, bags and luggage in the UK is being largely driven by value sales growth, with volume sales struggling. Lower demand compared to pre-pandemic levels is mainly due to declines in consumer spending in an inflationary environment. As consumers continue to face economic challenges, with bags an...
Despite a marginal retail value decline in 2024, demand for writing instruments in the UK continues to rise. Due to increasing engagement with the category during the pandemic and subsequent residual growth from this, sales growth of some writing instruments is starting to stabilise or fall in the c...
This Megatrends report highlights long-term trends resulting from shifts in consumer values and behaviour. It provides a summary of each of Euromonitor International's 10 focus megatrends and insights as to how each trend has manifested in the United Arab Emirates.
Euromonitor's ...
Ethnic apparel, particularly Indian womenswear, plays a significant role in boosting hosiery sales in the United Arab Emirates, largely due to the cultural preference for traditional attire during festivals, weddings, and formal occasions. Outfits such as sarees, lehengas, and kurtas are frequently ...
Trends in boys' and girls' apparel in the United Arab Emirates indicate a growing segment focused on sportswear and sports-inspired clothing. This shift is being driven by leading global brands such as adidas and Nike, as well as retailers such as Marks & Spencer, which are expanding their offerings...
Demand for jeans in the United Arab Emirates continues to grow in 2024, driven by the youthful population, primarily consisting of millennials and Generation Z. These demographics prioritise versatile and fashionable wardrobes, making jeans an ideal choice for their casual yet stylish preferences, a...
The demand for menswear in the United Arab Emirates continues to grow in 2024. The population in the United Arab Emirates is predominantly male, largely due to the influx of male workers in sectors such as construction and oil, which make up a significant portion of the labour force. This demographi...